GRI (GRI Bio Inc.) stock: $1.96, $4.3M market cap, $10.9M cash, -$6.6M EV, $5.1M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$1.96
Market cap
$4.3M
Cash
$10.9M
Enterprise value
-$6.6M
Balance sheet
Cash
$10.9M
Debt
$0.0M
Net cash
$10.9M
Enterprise value
-$6.6M
Basic shares
2.2M shares
Fully diluted shares
2.6M shares
Fully diluted market cap
$5.1M
Cash per share
$4.98
Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading GRI daily closes…
Loading price history…
Pipeline assets
GRI-0621
Phase 2 · ActiveModality: small molecule (oral)
Target type 1 iNKT cells (RAR-beta/gamma)
Partnerships Company retains global development and commercialization rights
Indications
Idiopathic pulmonary fibrosis (IPF)(Phase 2)
Status note Oral inhibitor of type 1 iNKT cells (active ingredient tazarotene). Completed randomized 12-week Phase 2a in IPF patients. FDA Orphan Drug Designation granted June 18, 2026. Evaluating Phase 2b/3 adaptive trial design with FDA feedback; requires substantial additional funding. Earlier pilot Phase 2a in chronic liver disease halted administratively. Going-concern warning disclosed.
GRI-0803
Preclinical · ActiveModality: small molecule (oral)
Target type 2 dNKT cells
Partnerships Company retains global development and commercialization rights
Status note Oral agonist of type 2 diverse NKT (dNKT) cells; lead molecule from 500+ compound library. Development previously limited pending funding; IND-enabling studies to be completed with IND filing for Phase 1a/1b in healthy volunteers expected first half of 2027.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.